The early decline in renal function in patients with type 1 diabetes and proteinuria predicts the risk of end stage renal disease by Skupien, Jan et al.
 
The early decline in renal function in patients with type 1 diabetes
and proteinuria predicts the risk of end stage renal disease
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Skupien, Jan, James H. Warram, Adam M. Smiles, Monika A.
Niewczas, Tomohito Gohda, Marcus G. Pezzolesi, Diego
Cantarovich, Robert Stanton, and Andrzej S. Krolewski. 2012. The
early decline in renal function in patients with type 1 diabetes and
proteinuria predicts the risk of end stage renal disease. Kidney
International 82(5): 589-597.
Published Version doi:10.1038/ki.2012.189
Accessed February 19, 2015 12:02:03 PM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:10611681
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAThe early decline in renal function in patients with type 1
diabetes and proteinuria predicts the risk of end stage renal
disease
Jan Skupien, MD PhD MPH1,2, James H. Warram, MD ScD1, Adam M. Smiles, MA1, Monika
A. Niewczas, MD PhD1,2, Tomohito Gohda, MD1,2,4, Marcus G. Pezzolesi, PhD1,2, Diego
Cantarovich, MD PhD5, Robert Stanton, MD1,3, and Andrzej S. Krolewski, MD PhD1,2
1Research and Clinic Divisions at Joslin Diabetes Center Harvard Medical School, Boston,
Massachusetts
2Department of Medicine at Brigham and Women Hospital, Harvard Medical School, Boston,
Massachusetts
3Renal Division at Beth Israel Deaconess Medical Center, Harvard Medical School, Boston,
Massachusetts
4Division of Nephrology, Department of Internal Medicine, Juntendo University School of
Medicine, Tokyo, Japan
5Institut de Transplantation, Urologie et Néphrologie (ITUN), Nantes University Hospital, Nantes,
France
Abstract
The risk of end-stage renal disease (ESRD) remains high in patients with type 1diabetes and
proteinuria; however, little is known about the rate of decline in their renal function. To help
determine this we enrolled patients with 1 diabetes and proteinuria whose estimated glomerular
filtration rate (eGFR) was normal (equal to or above 60 ml/min/1.73m2). Using a minimum of 5
serial measurements of serum creatinine for 161 patients, we determined individual trajectories of
eGFR change and the occurrence of ESRD during 5–18 years of follow-up. The rates were linear
for 110 patients, for 24 the non-linear rate was mild enough to satisfy a linear model, and the rates
were clearly non-linear for only 27 patients. Overall, in more than one third of patients, the eGFR
decline was less than 3.5 ml/min/1.73m2 per year and the lifetime risk of ESRD could be
considered negligible. In the remainder of patients, eGFR declined with widely different slopes
and ESRD developed within 2 to 18 years. Based on up to five years observation when renal
function was within the normal range, the estimates of early eGFR slope predicted the risk of
ESRD during subsequent follow-up better than the baseline clinical characteristics of glycated
hemoglobin, blood pressure, or the albumin to creatinine ratio. Thus, the early slope of eGFR
decline in patients with type 1diabetes and proteinuria can be used to predict the risk of ESRD.
INTRODUCTION
In our recent follow-up study, we found that patients with Type 1 Diabetes (T1D) and
proteinuria are at high risk of end stage renal disease (ESRD) despite nearly universal reno-
protective treatment (1). In those with normal serum creatinine-based estimated glomerular
filtration rate (eGFR ≥ 60 ml/min/1.73m2) at enrollment, the 15-year risk of ESRD was
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tapproximately 25%. FinnDiane study investigators reported a similar risk of ESRD in a
comparable cohort (2).
Knowledge of the course of renal function changes in patients with proteinuria due to
diabetes is limited. At one extreme of possible trajectories is a pattern with episodic declines
of renal function that is referred to as intermittent episodes of acute renal failure by some
authors (3). Such a pattern would suggest the involvement of stochastic processes that defy
prediction of the time until onset of ESRD. At the other extreme is a pattern with a constant
rate of decline in renal function. This pattern was first demonstrated empirically in a group
of 34 individuals with various renal conditions (4). Subsequent study of nine individuals
with diabetes and impaired renal function confirmed the linearity of the decline although
there was large inter-individual variation (5). Other early studies reported a linear GFR
decline but follow-up was short and study groups small (6–8).
As suggested by these examples, the shape of the trajectories over time and how it varies
among patients may provide important clues about the mechanisms that underlie progression
to ESRD. A stochastic process suggests a role of environmental triggers, and identification
of their nature calls for a particular type of study design. A constant decline, on the other
hand, suggests a constitutive determinant and calls for a different type of study design. For
example, a genetic factor would be detectable when renal function is still in the normal
range. Moreover, a constant slope implies that determination of the early slope while renal
function is normal could predict the late slope and, therefore, the risk of ESRD.
No prior study of patients with T1D and proteinuria has traced complete trajectories of renal
function changes from normal to ESRD. This report traces complete trajectories of renal
function change in the Joslin cohort of patients with T1D and proteinuria who were followed
for 5 to 18 years (1). Three questions guided the analysis. What patterns of trajectories of
renal function changes occur in this population? If linear, how varied are the overall slopes
of change during follow-up? To what extent can the early slope of eGFR decline predict
ESRD?
RESULTS
Characteristics of the Study Group
The study group comprised patients with T1D and proteinuria who were enrolled into the
Joslin Proteinuria Cohort study between 1991 and 2004 and followed through 2008 (1). All
were of European ancestry. This study was restricted to the 244 patients with normal renal
function (eGFR ≥ 60 ml/min) at enrollment. In the initial analysis to determine patterns of
trajectories of renal function changes, we used 161 patients (66% of the study group) who
had at least five measurements (range 5–73) of serum creatinine (see Methods). Clinical
characteristics of patients with frequent and less frequent measurements of serum creatinine
are summarized in Table 1. Those with less than five had shorter follow-up and a lower
number of creatinine measurements per year. Otherwise, the two sub-groups had very
similar clinical characteristics; therefore, we concluded that the patterns of trajectories of
renal function changes in those with frequent creatinine measurements were representative
of all 244 patients. All 244 patients were used for extracting the linear component of each
trajectory to generate a distribution of slopes of overall eGFR change during follow-up. For
evaluating the early slope of eGFR values as a predictor of ESRD risk, 28 had insufficient
early eGFR measurements for estimating an early slope (see Methods) and the remaining
216 were used.
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tPatterns of Trajectories of Renal Function Changes
The first step in the characterization of the trajectories was to determine whether they were
linear or non-linear. For this determination we modified an approach described by Jones and
Molitoris (9) and used by Shah and Levey (10) to test for non-linearity of an individual's
renal function changes during follow-up. The approach requires a minimum of five
observations, so this analysis was limited to the 161 patients with five or more
determinations of eGFR. It represents each patient's renal function trajectory as a simple
linear model and as a spline model with linear segments connected at an individually
determined point. Our modification was to allow more than two segments (three segments
were required in 2 patients and 5 segments in one individual). The spline and linear models
were compared, and a linear model was rejected at a nominal significance of 0.05 and
degrees of freedom determined by the number of spline segments (n-1).
The second step in the characterization of the trajectories was to classify the patient's eGFR
as stable or declining during follow-up. Our criterion for this distinction was based on
overall slope of eGFR decline. A slope less steep than 3.5 ml/min/1.73m2/year was
considered “stable” (Figure 1, A–C), while a steeper slope was considered clinically
significant decline (Figure 1, D–F). See Methods for the motivation underlying this
criterion.
The third characterization applied only to individuals with significantly non-linear
trajectories and was based on the clinical consequences of the deviations from linearity. For
individuals with stable renal function, we concluded that the deviations from linearity had
no clinical consequence (Figure 1 C). For patients with declining renal function, the non-
linearity of a trajectory was considered clinically inconsequential (Figure 1, E) if the
estimated time of reaching eGFR = 10 ml/min/1.73m2 (expected time of ESRD) was within
one year of the observed time of ESRD (vertical dotted line). If the difference was larger,
the non-linearity of the trajectory was considered clinically consequential. These non-linear
trajectories were further characterized as decelerating (Figure 1, G) or accelerating (Figure
1, H and I). Typically, acceleration interrupted a period of stable renal function (new-onset
decline) as in example H. Example I illustrates a rare pattern, acceleration from one rate of
decline to a faster one. Neither acceleration nor deceleration was significantly associated
with RAS blockade.
The frequencies of these different patterns are summarized in Table 2. The trajectories of
110 patients (68.3%) were adequately fitted by a simple linear model, 59 stable (36.6 %) and
51 (31.7 %) declining. The trajectories for another 24 (14.9%) were significantly non-linear,
but the non-linearity was clinically inconsequential, 16 stable (9.9 %) and 8 declining (5.0
%). Thus, for clinical purposes, a linear model adequately represented the trajectories of a
total of 134 patients (83%). The non-linearity of the trajectories for the remaining 27 (17%)
patients was clinically consequential, 20 (12.4%) experiencing deceleration and 7 (4.4%)
experiencing acceleration.
Inter-individual Variation in Trajectories of Renal Function Changes
To gain an appreciation of the distribution of the overall rate of eGFR decline in the whole
group of 244 subjects, we extracted the linear component of each trajectory as a simple
slope (Figure 2). A few individuals had a positive slope, i.e. improved in renal function at
the end of follow-up (n=25), but the majority had negative slopes, i.e. declining renal
function. The median (25th, 75th percentiles) was −2.9 (−7.1, −1.27) ml/min/1.73m2/year.
Reflecting the long tail of negative values, the 5th percentile was −16.8 and the minimum
−70.5 ml/min/1.73m2/year. The fastest eGFR decline is shown in Figure 1, F. The available
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tclinical information for this patient did not indicate any other cause of renal function decline
than T1D (See Appendix 1 for more details).
Exclusion of the slope estimates for patients with non-linear or unknown trajectories did not
materially change the shape of the distribution of slopes (insert in Figure 2) or the median
(−2.6 as compared to −2.9 ml/min/1.73m2/year).
Prediction of ESRD risk from the early eGFR slope
The observation that a simple linear model of renal function decline gave satisfactory
predictions of renal outcomes for most patients prompted the question whether data obtained
during early follow-up provide useful prognostic information. When a T1D patient presents
with proteinuria and normal renal function, monitoring of eGFR will generally begin. We
sought to examine how well a slope fitted to these early determinations of eGFR predicts the
risk of ESRD. To mimic this situation, we restricted the measurements to the first 5 years of
follow-up and those made while patients remained in CKD stages 1 or 2 (eGFR ≥60 ml/min/
1.73m2). Only 216 patients had at least two serum creatinine measurements for estimating a
slope that met these restrictions. The median early slope was −3.8 ml/min/1.73m2/year, and
it did not differ significantly from the median slope estimated from complete follow-up
(p=0.45). The 25th and 75th percentiles were −8.5 and −1.0, respectively and the steepest
early slope was −66.0 ml/min/1.73m2/year, observed in the patient presented in Figure 1F.
With Cox proportional hazards models we evaluated this early eGFR slope as a predictor of
time to ESRD during subsequent follow-up after the initial period used for estimating the
early slope. We compared its performance with that of common clinical risk indicators:
albumin to creatinine ratio (ACR), glycated hemoglobin (HbA1c) and systolic blood
pressure. The early eGFR slope was strongly associated with time to ESRD (p<0.0001).
With a C-index of 0.77 (95% CI: 0.70, 0.84), it was a stronger predictor than traditional risk
indicators: ACR, HbA1c and systolic blood pressure, singly or in combination (Table 3).
Prognostic criteria for early eGFR slope
To determine simple criteria suitable for assigning an ESRD risk to values of the early eGFR
slope, we searched the range of early eGFR slopes for cut-points (thresholds) that produced
the maximum separation of the risk of ESRD for two resulting groups, measured by the chi-
square for a log-rank test. For this analysis the time to ESRD was measured from the last
observation used to estimate the early eGFR slope. A cut-point of −11 ml/min/1.73m2/year
produced the largest separation, cumulative risk of 50.2% for those with steeper eGFR
declines and 7.0% for those with shallower declines (Figure 3). As a screening test to
diagnose patients who would reach ESRD within five years, its sensitivity was 65% and
specificity 90%. Repeat application of this procedure to the range of slopes less steep then
the cut-point of −11 ml/min/1.73m2/year yielded a second cut-point of −6.5 ml/min/1.73m2/
year. The cumulative risk at five years for the middle range (−11 to −6.5 ml/min/1.73m2/
year) was 18.4% and was only 3.6% for the shallowest slopes (Figure 3). Viewed as a
screening test to distinguish patients who will remain free of ESRD for five years, this cut-
point has a sensitivity of 75% and a specificity of 84%.
DISCUSSION
In this study of patients with proteinuria due to T1D, we determined the trajectory of each
individual's change in eGFR from its initially normal value for up to 18 years. We found that
the majority of these trajectories are well represented by a simple regression line. Renal
function was stable throughout follow-up in approximately a third of the patients, suggesting
that their lifetime risk of ESRD is very low. In the remaining two thirds of the patients, renal
function declined significantly, but at rates that vary widely among individuals. Observed
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ttimes to onset of ESRD ranged from 1.3 to 17.3 years. These results invite consideration of
both the nature of the determinants of the variation among individuals in the rate of eGFR
decline and the feasibility of developing means of predicting time to ESRD in patients with
T1D and proteinuria.
These findings in patients with T1D and proteinuria can be considered an extension of our
previous study of renal function loss in T1D patients with a milder abnormality of urinary
albumin excretion, microalbuminuria (11–13). In that 4–12 year follow-up study, we used
serial measurements of serum cystatin C to examine the trajectories of eGFR changes.
Significant renal function loss developed in one out of three patients. Initially, renal function
was either normal or even elevated, and then began to decline at the onset of
microalbuminuria. The rate of loss was highly variable among individuals yet remained
constant within individuals (11). In the present study of T1D patients with normal renal
function and proteinuria, significant renal function loss occurred in two out of three patients
during the 5–18 year of follow-up. As in the previous study, the rate of loss was highly
variable among individuals yet remained constant within individuals.
The mechanisms that initiate renal function decline in patients while function is still normal
are unknown. Also uncertain is whether those initial mechanisms remain in operation as
renal function decline progresses through advanced CKD stages. The “final common
pathway” hypothesis posits two phases of renal function decline (14, 15). Regardless of the
nature of the initial injury, a shift in pathology occurs at a certain point that is self-propelling
and possibly accelerating. As noted above, however, the majority of patients experiencing
eGFR decline in this study maintained a constant rate of loss as they passed from CKD
stages 1 and 2 (early eGFR decline) through stages 3 and 4 (late eGFR decline).
A few hypotheses can be offered to explain an overall pattern that includes a constant rate of
decline within individuals and large variability of that rate among individuals. First, the
process underlying loss must be fully developed when it is initiated and usually does not
evolve over time. Although its initiation is likely triggered by environmental factors, the
constant rate of decline is most likely the effect of constitutional susceptibilities such as
genetic factors. If the latter is true, multiple genes and probably multiple variants within
genes are likely required to account for the large differences among individuals in the rate of
eGFR decline (Figure 2). Dissection of the genetic architecture of diabetic nephropathy will
best be achieved by studies of the rate of eGFR as a quantitative phenotype rather than by
case control studies.
The patients with T1D and proteinuria in the present study had earlier been members of the
population of T1D patients with microalbuminuria. They comprise two major
subpopulations: 1) those in whom early renal function decline was already present when
they entered this study population, and 2) those whose renal function remained normal and
stable as albumin excretion progressed to proteinuria. The subpopulation with stable renal
function is much larger than generally perceived, and this finding must be conveyed to
physicians so they can advise patients more appropriately that not all patients with
proteinuria are at high risk of ESRD. Diagnostic tools (serum or urinary biomarkers or DNA
sequence variants) that distinguish patients with declining renal function from those with
stable function are highly desirable. Until such tools become available, we propose that
serum creatinine be measured frequently in T1D patients with proteinuria. These
measurements can be used to estimate the early eGFR slope, which appears to be a stronger
predictor of the risk of ESRD than other clinically available characteristics.
Whether estimates of the slope of early eGFR decline can be clinically useful for predicting
the precise time for initiating renal replacement therapy well in advance remains to be
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tevaluated. In the meantime, however, it can be used to stratify subjects according to ESRD
risk and urgency for intervention. Clinical trials of progressively more invasive or drastic
therapies to prevent or postpone ESRD become feasible if such patients can be selected that
their risk of ESRD outweighs the associated discomfort and complications.
We used eGFR determinations made before CKD stage 3 was reached out to a maximum of
five years of follow-up. The actual follow-up time used to estimate the slope was shorter
than five years for fast decliners who reached CKD stage 3 early. With denser and more
equally spaced eGFR determinations, it is potentially possible to improve the predictive
performance of the early eGFR slope or reduce the observation time required to obtain a
satisfactory estimate of the slope. This issue requires prospective investigation with an
appropriate study design.
Another potential application of the slope of early eGFR decline would be its development
and validation as a surrogate outcome measure. Currently, evaluations of novel therapies to
prevent ESRD focus on individuals with significantly impaired renal function. Quite likely,
trial interventions that retard the rate of renal function decline will be less effective in
patients with already impaired renal function than in those at earlier disease stage. Thus, the
slope of early eGFR changes deserves evaluation as a candidate for ESRD surrogate marker.
Most of the literature on trajectories of eGFR leading to ESRD has focused on small groups
of decliners, predominantly non-diabetic, who already had significantly impaired renal
function. The slope of renal function decline was constant in the majority of studies (4–8,
16), suggesting the feasibility of predicting of ESRD onset from serial renal function
estimates from early stages of CKD. Some authors questioned this conclusion (10, 17) but
also noted that, for the majority of subjects, predicted times to ESRD from linear and non-
linear models differed by less than a year (10).
We studied patients with normal renal function and fitted linear and spline models to their
trajectories of eGFR changes (9, 10). Our conclusion of the predominance of linear eGFR
trajectories is robust given our relatively non-stringent statistical criteria for rejecting
linearity. Instead of greater stringency, we supplemented statistical criteria with criteria
based on the clinical consequences of discrepancies between linear and non-linear models.
Although our study has many strengths, we acknowledge real and perceived limitations.
First, the prevalence of treatment with ACE-I and/or ARB at enrolment was lower than
currently prescribed. This was because ascertainment of the cohort started in the early 1990s
when the use of ACE-I was just coming into vogue. The prevalence of ACE-I and ARB
treatment increased from 56% in 1991–1995 to 82% in 2001–2004. Noteworthy is the
observation that despite this increase in use of RAS blockade, the risk of ESRD was
unchanged and remains high (1). Moreover, RAS blockade was not associated with the slope
of renal function decline or the probability of deceleration of decline. It has been suggested
that the RAS blockade, although has proven efficacy in a number of trials, may not be
sufficiently effective in a clinical setting (18).
Second, we recruited proteinuria cases with normal renal function. Since this group included
prevalent as well as incident cases of proteinuria, and non-decliners accumulate among
prevalent cases, the proportion of non-decliners is higher than would be found if all patients
were incident cases. Furthermore, our study included only patients with proteinuria due to
diabetes. It is not clear that the findings would be the same in patients without diabetes.
Finally, we did not have direct measurements of GFR in our study. However, direct methods
of measuring GFR have their own limitations. For example, as clearly demonstrated in Pima
Indians (19), iothalamate clearance is affected by enormous intra-day variations within an
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tindividual, a characteristic that limits the value of direct determinations of GFR in
estimating the slope of renal function decline.
In summary, the predominantly constant rate of eGFR loss observed in this study through all
stages of CKD suggests that this process is, to a large extent, predictable and that the risk of
ESRD, can be reasonably well inferred from the early slopes of eGFR changes over a 5-year
period of observation. Early eGFR slopes calculated under the linearity assumption carry
sufficient information for reliable risk stratification. Further research on the determinants
and mechanisms of early renal function decline in patients with T1D and proteinuria is
necessary to develop new therapies to reduce the risk of ESRD (1).
METHODS
Population
Patients in this study are members of the Joslin Proteinuria Cohort (n=423). Informed
consent procedures and protocols for patient examinations at study entry and during follow-
up were approved by the Joslin IRB, as were methods for ascertaining all cases of ESRD or
death during 5–18 years follow-up. Details of these methods and description of the natural
history of the development of ESRD in this cohort have been published (1).
Assessment of proteinuria
The diagnoses of proteinuria were made in random urines by determinations of the urinary
albumin to creatinine ratio (ACR) or meter readings of Multistix test strips (Ames, Miles
Laboratories, Elkhart, IN, USA). Proteinuria is diagnosed if the ACR (in mg/g) is ≥250 in
men or ≥355 in women or the Multistix reading is ≥2+ (corresponding to albumin
concentration ≈1000 μg/ml) in two out of three consecutive urine samples. A higher ACR is
required for women due to their lower creatinine concentrations. When calibrated to timed
measurements of albumin excretion, these sex-specific ACR criteria are equivalent to an
albumin excretion rate (AER) of 300 μg/min (20).
Albumin was measured by immunonephelometry on a BN100 with N Albumin kits
(Behring, Somerville, NJ, USA), with intra-assay and inter-assay coefficients of variation
<3% and 5%, respectively. Creatinine measurements were assayed by Jaffe's modified
picrate method on a Ciba Corning Express Plus Chemistry Analyzer (inter and intra-assay
coefficients of variation 2.3% and 3.5%, respectively). Separate from the determinations
used for the diagnosis of proteinuria, the urinary ACR was determined in a sample obtained
at the baseline examination of all patients.
Assessment of renal function
We used serum creatinine concentration and the CKD-EPI formula (21) to estimate renal
function (eGFR) at study entry and during follow-up. In 2009, serum creatinine was
measured in all 1,379 stored study samples (423 from baseline and 956 from follow-up
examinations) at the University of Minnesota using the Roche enzymatic assay (Prod No.
11775685) on a Roche/Hitache Mod P analyzer. This method is calibrated to be traceable to
an isotope dilution mass spectrometry (IDMS) reference assay and was verified by
measuring National Institutes of Standards and Technology Standard Reference Material
(NIST SRM) No. 967.
We retrieved 4,567 measurements of serum creatinine performed in the 423 patients during
routine clinic visits from the Joslin Clinical Laboratory records. These measurements were
assayed by Jaffe's modified picrate method on a Ciba Corning Express Plus Chemistry
Analyzer (inter and intra-assay coefficients of variation 2.3% and 3.5%, respectively). For
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t1133 (24.8%) samples, the clinical measurement was made on the same blood draw as the
measurement at the University of Minnesota because the routine visit coincided with a study
examination. We used these duplicate measurements to calibrate the clinical measurements
to the assay method of the reference laboratory.
Onset of ESRD was determined by matching the study roster against the United States Renal
Data System (USRDS) and recorded as the date of first renal transplant or renal dialysis, as
described previously (1).
Study Group
To characterize the complete trajectories of eGFR decline from normal to ESRD, we
restricted this study to the 244 patients in the Joslin Proteinuria Cohort whose renal function
was normal at study entry (eGFR ≥ 60 ml/min/1.73m2). For these participants, 2955 follow-
up measurements of serum creatinine (calibrated to the reference laboratory) were available
to trace the course of eGFR over time.
Trajectories of eGFR Decline During Follow-up
We followed an approach described by Jones and Molitoris (9) and used by Shah and Levey
(10) to model an individual's serial estimates of renal function. A minimum of five
observations is required (9), so only 161 (66.0%) of our study group and their 2723 eGFR
determinations were used. The approach represents each patient's renal function trajectory as
a simple linear model and as a spline model with linear segments connected at a point
determined by a search for minimum residual sum of squaes. Our modification was to allow
more than two segments (three segments were required in 2 patients and 5 segments in one
individual). The spline and linear models were compared and a linear model was rejected at
a nominal significance of 0.05 and degrees of freedom determined by the number of spline
segments (n-1).
Selection of a cut-point to distinguish stable from declining trajectories was necessarily
somewhat arbitrary. Practical considerations support a decline of 3.5 ml/min/1.73m2 as a
reasonable choice. For an individual with this rate of decline and a beginning eGFR of 95
ml/min/1.73m2 (the mean in our study group), ten years would be required to reach CKD
stage 3 and 25 years to reach ESRD. This choice also has some empirical support. Studies in
the general population reported mean slopes of renal function decline between −0.5 and −2.5
ml/min/1.73m2 per year (22–27). We assumed a mean age-related decline of −1.0 ml/min/
1.73m2/year as other authors have (28, 29) and a standard deviation of 2.0, as extracted from
published reports (22–27). If the distribution is normal, the 10th percentile of distribution of
eGFR slopes would be −3.5 ml/min/1.73m2/year.
All individuals with stable renal function were considered well characterized by a linear
model of renal function changes, since deviations from linearity in overall non-declining
trajectory are of little clinical consequence. In decliners we considered over 1-year
difference between observed time of ESRD and time of reaching eGFR = 10 ml/min/1.73m2
(expected time of ESRD) under linear model as clinically consequential.
Inter-individual Variation in Slope of eGFR Decline
To estimate and describe inter-individual variation in the slope of eGFR decline, we
extracted the linear component of every subject's trajectory in the complete cohort of 244
individuals, including the 83 with less than five measurements. The onset of ESRD was
typically not accompanied by a measurement of serum creatinine in the Joslin Clinic
laboratory. Therefore, we assumed the eGFR was 10 ml/min/1.73m2 at that time.
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When a patient presents clinically with T1D, normal renal function and proteinuria, the
eGFR is monitored. After five years, the early slope of eGFR values can be determined. To
mimic this situation, we estimated early slope during the first five years of follow-up while
patients remained in CKD stages 1 or 2 (eGFR ≥60 ml/min/1.73m2) and investigated its
potential as a predictor of progression to ESRD from that point during subsequent follow-
up. The analysis was restricted to patients with at least two serum creatinine measurements
(n=216) before reaching their fifth enrollment anniversary or CKD stage 3. We compared its
performance as a predictor with that of common clinical risk indicators: albumin to
creatinine ratio (ACR), glycated hemoglobin (HbA1c) and systolic blood pressure in Cox
proportional hazards models using the C-index, a generalized discrimination index for
survival data, as defined by Harrell (30).
Statistical Methods
Statistical significance was set at a P-value less than 0.05. Analyses were conducted in SAS
for Windows, version 9.2 (SAS Institute, Cary, NC). Characteristics of patients were
summarized by percentages, means and standard deviations or medians and quartiles. The
linear component of renal function trajectories was estimated with linear regression, and
linear spline models were fitted with least squares method, as proposed by Jones and
Molitoris (7) and extended to allow for multiple knots. The cumulative risk of ESRD was
estimated by the Kaplan-Meier method. Predictive performance of early eGFR slope and
clinical markers was evaluated with C-index (30) in simple and multiple Cox proportional
hazards models. We then searched the range of early slopes of eGFR decline for cut-points
(thresholds) that produced the maximum chi-square (log-rank test) for the separation
between survival curves for the two resulting groups, as proposed by Contal and O'Quigley
(31).
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Appendix 1
The individual with the most rapid renal function decline was a 25-year old woman with 15-
year history of diabetes. At the time of study entry her eGFR was 89.4 ml/min/1.73m2, ACR
was 766 mg/g and HbA1c 8.5%. She was normotensive (116/78 mmHg) and did not take
ACE-I or ARB. Decline of her renal function could be tracked five months before
enrollment, when her eGFR was 128 ml/min/1.73m2 and 108 ml/min/1.73m2 four months
later. She progressed to ESRD within 15 months, during which time her glycemic and blood
pressure control deteriorated (HbA1c in the range 9–11%, blood pressure 140–150/90–100).
Within a month after study entry, her urinary protein level increased rapidly to 2.2 g/24h.
Four months into follow-up, the patient became pregnant and subsequently terminated. This
episode took place after the onset of renal function decline and did not change the slope
(Figure 1 F). The urinalyses in her record were unremarkable (no apparently active
sediments). Kidney biopsy was not available. Thus, one certainly cannot definitively rule out
another kidney disease, but it is likely that diabetes was a major cause of her decline in GFR.
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Patterns of renal function decline: A, B Linear trajectories, stable renal function; C Stable
renal function, clinically inconsequential non-linear trajectory; D and F Linear decliners; E
Decliner with clinically inconsequential non-linear trajectory (observed time of ESRD is
within 1 year from time of reaching eGFR=10 under linear model); G–I Non-linear decline;
G Deceleration; H New-onset decline (acceleration); I Acceleration. Dots represent single
eGFR measurements and solid lines represent linear spline function. Dotted line represents
linear regression. Vertical dotted lines mark the observed time of ESRD onset.
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Distribution of slopes of eGFR decline according to 2 ml/min intervals in 244 subjects with
proteinuria (large figure). The three patients in the interval <−32 had slopes −52.5, −56.4
and −70.5 ml/min/1.73m2/year. (Inset: the distribution of slopes in the sub-set of 112
patients with linear trajectories of eGFR decline)
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tFigure 3.
Cumulative incidence of ESRD according to various cut-points of slopes of early eGFR
decline in ml/min/1.73m2/year. Cumulative incidence of ESRD is presented according to
years of follow-up after the last measurement used to estimate early eGFR slope.
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Table 1
Characteristics of the study group according to number of serum creatinine measurements
Number of serum creatinine determinations during follow-up
Characteristic Total group
N=244
≥5 measurements
N=161
<5 measurements
N=83 P-value*
At baseline
Men (%) 56.6 55.9 57.8 0.77
Age (y) 36.8±8.4 36.9±8.6 36.6±8.0 0.78
Diabetes duration (y) 24.1±8.2 23.8±8.2 24.6±8.4 0.45
Age at diagnosis (y) 12.8±8.0 13.2±8.5 12.0±7.1 0.25
Urinary ACR (mg/g) 676 (430, 1238) 682 (434, 1300) 637 (396, 1156) 0.45
Hemoglobin A1c (%) 9.0±1.7 9.1±1.6 8.9±1.9 0.34
Systolic blood pressure (mmHg) 131±18 132±18 131±16 0.62
Diastolic blood pressure (mmHg) 78±10 78±10 79±9 0.22
ACE-I or ARB treatment (%) 66.0 65.8 66.3 0.95
eGFR (ml/min/1.73m2) 95±19 95±19 95±19 0.97
Body mass index (kg/m2) 26.7±5.8 26.8±6.3 26.6±5.6 0.86
Total cholesterol (mg/dl) 212.2±49.0 212.6±52.7 212.0±47.2 0.92
HDL cholesterol (mg/dl) 55.3±17.4 59.1±19.6 53.4±15.9 0.02
Statin treatment (%) 17.2 19.3 16.2 0.54
Current smoking (%) 26.9 29.1 22.5 0.28
During follow-up
Length of follow-up (yrs) 7.4 (5.5, 12.2) 9.0 (6.1, 13.3) 6.2 (4.6, 8.9) ---
Creatinine measurements (N) 7.5 (4, 18) 13 (8, 22) 3 (2, 4) ---
Creatinines per year (N) 1.1 (0.5, 1.9) 1.6 (1.0, 2.4) 0.5 (0.3, 0.6) ---
Incidence rate of ESRD† 2.4 (51) 2.1 (33) 3.2 (18) 0.12
Mortality rate unrelated to ESRD† 0.8 (18) 0.7 (12) 1.1 (6) 0.47
Data are percent, mean±standard deviation or median (25th, 75th percentile).
ACR=albumin to creatinine ratio, ACEI=angiotensin converting enzyme inhibitor, ARB=angiotensin receptor blocker
*
P-value is for the comparison between patients with <5 measurements and those with ≥5 measurements.
†
per 100 person years (number of events)
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Table 2
Distribution of trajectories of eGFR changes according to presence of non-linearity, significant decline, and
the direction of slope change for non-linear patterns
N Percent
A. Linear 110 68.3
  Stable (Figure 1, A and B) 59 36.6
  Decline* (Figure 1, D and F) 51 (20)† 31.7
B. Clinically inconsequential non-linearity 24 14.9
  Stable (Figure 1, C) 16 9.9
  Decline* (Figure 1, E) 8 (8)† 5.0
C. Clinically consequential non-linearity 27 16.8
  Deceleration (Figure 1, G) 20 (2)† 12.4
  Acceleration (Figure 1, H and I) 7 (3)† 4.4
Criteria for classifying trajectories as non-linear and of clinical consequence are in Methods.
*
An eGFR decline of 3.5 ml/min/1.73m2/year or more
†
(Number of individuals reaching ESRD)
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Table 3
Associations of the early slope of eGFR decline in CKD stages 1–2 and of known risk factors with the risk of
ESRD
Model Predictor Hazard ratio* P-value C-index
1 Slope of early decline 1.31 (1.18, 1.44) <0.0001 0.77 (0.70, 0.84)
2 Urinary ACR 1.30 (1.05, 1.60) 0.015 0.72 (0.64, 0.80)
3 Hemoglobin A1c 1.43 (1.18, 1.73) 0.0003 0.69 (0.62, 0.76)
4 Systolic blood pressure 1.06 (0.74, 1.54) 0.69 0.51 (0.40, 0.62)
5 BMI 0.79 (0.54, 1.15) 0.22 0.53 (0.43, 0.63)
6 ACE-I or ARB treatment 0.67 (0.39, 1.17) 0.16 0.59 (0.51, 0.66)
7 Smoking 1.55 (0.79, 3.02) 0.20 0.56 (0.48, 0.64)
8 Model 2+3 - - 0.72 (0.65, 0.79)
9 Model 8+ slope - - 0.80 (0.73, 0.86)
ACR: urinary albumin to creatinine ratio
Hemoglobin A1c: glycated hemoglobin A1c
ACE-I: angiotensin converting enzyme inhibition
ARB: angiotensin receptor blocker
Only variables significant in univariate analysis enter models 8 and 9. The strength of prediction of each model, in terms of discrimination, is
described by C-index, where a value 0.5 indicates a useless marker and 1.0 is perfect risk discrimination.
Data are point estimate (95% confidence interval).
*
HR are expressed for 5 ml/min/1.73m2/year change in slope, 1000 mg/g increase in ACR, 1% increase in HbA1c, 20 mmHg increase in blood
pressure and 5-unit increase in BMI. For ACE-I or ARB treatment status, or smoking the effect of “present” vs. “absent” is shown.
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